In a 64-week clinical trial , the Wegovy pill resulted in an average weight loss of 13.6%, and in a 68-week clinical trial, the Wegovy injection produced an average weight loss of 14.9%
First, the mechanical agitation subjects peptide chains to shear forces at the liquid-air interface
Medication eligibility and prescriptions are determined solely by licensed medical providers based on clinical appropriateness
With this triple action, early trials have shown, this GLP-3 to be even more effective than the currently available weight-loss medications
People with federal, state, or government-funded insurance plans, such as Medicare or TRICARE, cannot use these programs